Compugen Ltd. (NASDAQ:CGEN) was up 4.8% on Friday . The stock traded as high as $7.22 and last traded at $7.20, with a volume of 181,768 shares traded. The stock had previously closed at $6.87.

Several equities research analysts have recently weighed in on CGEN shares. FBR & Co reaffirmed a “buy” rating on shares of Compugen in a report on Wednesday, June 22nd. Zacks Investment Research raised shares of Compugen from a “sell” rating to a “hold” rating in a report on Tuesday, August 2nd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $10.25.

The company has a 50 day moving average price of $6.65 and a 200 day moving average price of $6.16. The company’s market cap is $361.96 million.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.04. On average, equities research analysts forecast that Compugen Ltd. will post ($0.56) earnings per share for the current year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.